Latest News
Bloom Energy Joins S&P 500, Yet Shares Slip 5.4% on Rebalance Day
Bloom Energy's S&P 500 debut was met with a 5.4% stock decline on Friday, as investors took profits after the index addition was announced.
Trade Desk Tumbles 2.4% Ahead of Index Exit; Option Repricing Vote Looms
Trade Desk (TTD) closed down 2.4% at $13.92 on heavy volume before its S&P 500 exit. A shareholder vote on repricing up to 15.6 million employee options is set for Oct 19.
Eli Lilly's Inluriyo-Verzenio Combo Gains FDA Nod, Shares Steady
FDA approved Eli Lilly's Inluriyo-Verzenio combo for ESR1-mutated breast cancer. Shares closed nearly flat at $1,152.93 as the approval expands an existing franchise.
Sandisk's S&P 100 Debut: Index Rally Meets NAND Pricing Reality
Sandisk's S&P 100 inclusion sparked an 11% rally, but the focus now shifts to NAND pricing trends and the company's ability to sustain high margins.
Peso Slides as Fed Hike Trims Mexico Rate Edge
The Mexican peso weakened 0.4% against the dollar as the Fed's first 2026 hike cut Mexico's rate premium. USD/MXN rose to 17.2333. Banxico meets Sept. 24.
Firmus IPO: Founders' Staged Exit Raises Questions Amid Missing Prospectus
Firmus founders can sell a portion of their stakes one year after the IPO, but the absence of a prospectus leaves investors guessing about valuation and financials.
Boeing 787-9 Back in Service as United Jet Returns to Skies
A United Airlines 787-9 that faced early maintenance issues is back in service, with no fleet-wide grounding. Boeing and United shares show no market shock.
MARA Surges 13.7% as Morgan Stanley's New Target Falls Short
MARA Holdings shares rallied 13.7% to $13.24, closing above Morgan Stanley's new $11 target. Bitcoin's rebound and AI data center plans fuel the surge.
Netflix Shares Slide 4.7% as Wells Fargo Flags Content Strategy Risks
Netflix (NFLX) dropped 4.7% Friday after Wells Fargo downgraded the stock, citing weaker engagement and content trade-offs. The new $57 target implies 20.6% downside.
Xenon Pharma Stock Plunges 31% on Psychiatry Trial Halt
Xenon Pharmaceuticals shares tumbled 30.7% after pausing enrollment in depression studies due to neuropsychiatric adverse events, overshadowing its FDA filing for azetukalner in epilepsy.
MSTR Surges 15.8% as Leverage Amplifies Bitcoin Rally
Strategy (MSTR) rallies 15.8% as Bitcoin gains 6.35%, but the move reflects leverage, not new purchases. Investors should focus on net asset value after senior claims.